Compare GE Aerospace (GE) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs GE HealthCare Technologies Inc. Common Stock — how do they compare? GE Aerospace trades at $308.79 (market cap $319.19B), while GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B). The key difference: GE Aerospace is far larger — about 10.3× GE HealthCare Technologies Inc. Common Stock's market cap, and GE Aerospace pays the higher dividend (0.61%). Which is the better fit depends on your goals.
| GE | GEHC | |
|---|---|---|
Market Cap | $319.19B | $31.07B |
Volume | 4,516,693 | 3,443,020 |
Sector | Industrials | Health |
52-Week High | $381.22 | $88.16 |
52-Week Low | $273.25 | $59.48 |
Typical Hold Time | 111 Days | — |
Enterprise Value | $329.00B | $39.53B |
Dividend Yield | 0.61% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $308.64, showing modest daily gains of 0.14% amid mixed technical signals. The stock maintains strong fundamentals with three consecutive quarterly earnings beats, robust 48.79% ROE, and improving profit margins reaching 18.98% in 2025. Recent news highlights the company's $12 billion CPP acquisition to strengthen its aerospace supply chain capabilities while maintaining shareholder returns through dividends and buybacks.
Outlook remains positive with analyst consensus at $409.60 price target (32.7% upside) and no sell ratings. Key opportunities include aerospace demand growth and strategic acquisitions, while risks involve high valuation multiples (P/E 36.28) and integration challenges from recent M&A activity. The bearish technical picture suggests potential near-term consolidation before fundamental strengths drive long-term appreciation.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
